Qutenza (Capsaicin 8% Patch)

What Is Qutenza and What Is It Used For?

Qutenza belongs to the anesthetic drug class and contains capsaicin, the naturally occurring compound found in chili peppers that gives them their characteristic heat. Unlike low-concentration capsaicin creams available over the counter, Qutenza delivers a therapeutic dose of capsaicin at 8% (640 micrograms per square centimeter) via a large cutaneous patch measuring 14 × 20 cm (280 cm²). This high concentration is what makes Qutenza uniquely effective for treating established neuropathic pain conditions.

Qutenza is specifically indicated for the treatment of peripheral neuropathic pain in adults, either as monotherapy or in combination with other analgesic medications. Peripheral neuropathic pain is caused by damage to or dysfunction of sensory nerves in the peripheral nervous system – the network of nerves outside the brain and spinal cord. This type of pain is often described as burning, shooting, stabbing, or electric shock-like sensations, and it can be profoundly debilitating, affecting sleep, mood, and quality of life.

The conditions for which Qutenza has demonstrated efficacy in clinical trials include:

• Postherpetic neuralgia (PHN) – chronic nerve pain following a shingles (herpes zoster) infection, the most commonly studied indication for Qutenza
• Diabetic peripheral neuropathy (DPN) – nerve damage caused by diabetes mellitus, typically affecting the feet and lower legs
• HIV-associated neuropathy – nerve pain resulting from HIV infection or antiretroviral treatment
• Post-surgical and post-traumatic neuropathy – nerve pain following surgery or physical injury to nerves
• Other peripheral neuropathies – neuropathic pain from various causes affecting peripheral nerves in the skin

The mechanism of action of Qutenza is distinctive. Capsaicin selectively activates the transient receptor potential vanilloid 1 (TRPV1) receptor on nociceptive C-fibers and A-delta nerve fibers in the skin. This initial activation causes a brief period of intense stimulation (the burning sensation patients feel during application), followed by a prolonged period of desensitization where the nerve endings become less responsive to painful stimuli. With sustained exposure at high concentrations, capsaicin causes a reversible “defunctionalization” of the nociceptor nerve endings, reducing the density of TRPV1-expressing epidermal nerve fibers. This results in meaningful pain relief that typically begins 1–3 weeks after treatment and can last for up to 12 weeks.

Importantly, only very small amounts of capsaicin enter the systemic circulation during treatment, meaning that Qutenza acts locally at the site of application rather than throughout the body. This targeted mechanism helps minimize systemic side effects compared to oral pain medications such as opioids, anticonvulsants, or antidepressants commonly used for neuropathic pain.

What Should You Know Before Using Qutenza?

Contraindications

Qutenza must not be used if you have a known allergy (hypersensitivity) to capsaicin, which also occurs naturally in chili peppers, or to any of the other ingredients in the patch or the accompanying cleansing gel. Patients with a known history of allergy to chili peppers or capsaicin-containing products should inform their healthcare provider before treatment.

Warnings and Precautions

Before receiving Qutenza treatment, it is essential that your healthcare provider conducts a thorough assessment of your medical history and current health status. Several important precautions apply to the use of this medication:

Cardiovascular considerations: Qutenza application can be painful, and this pain may cause a temporary increase in blood pressure. For this reason, your doctor will measure your blood pressure multiple times during the treatment. If you have unstable or poorly controlled high blood pressure, or a history of cardiovascular events such as heart attack, angina, or arrhythmias, your doctor will carefully weigh the risks and benefits of treatment before proceeding. The stress of the application procedure may potentially trigger adverse cardiovascular events in vulnerable patients.

Application-site reactions: It is entirely normal for the skin to become red, feel warm, and sting or burn during and immediately after Qutenza treatment. These local reactions are a direct pharmacological effect of capsaicin and do not indicate an allergic reaction. However, in rare cases, more severe reactions may develop, including deep redness, blistering, skin ulceration, or burn-like injuries. If you experience unusually severe or prolonged pain during the procedure, your healthcare provider may remove the patch early and apply cooling measures or administer analgesic medication.

Sensory changes: Following Qutenza application, small and usually temporary changes in the ability to detect heat and sharp stimuli may occur at the treatment site. These sensory alterations reflect the mechanism of action (nociceptor defunctionalization) and typically resolve spontaneously. Patients should be advised to take care with hot objects and sharp surfaces near the treated area until normal sensation returns.

Inhalation risk: Capsaicin particles from the patch can become airborne during handling. Sniffing or inhaling near the patch may cause coughing, throat irritation, and sneezing. Healthcare personnel handling the patches typically wear masks and protective eyewear, and treatment rooms should be well-ventilated.

Pregnancy and Breastfeeding

Qutenza should be used with caution during pregnancy. There are limited data on the use of capsaicin in pregnant women, and the potential risk to the developing fetus is not fully established. Animal reproduction studies have not demonstrated teratogenic effects, but as with all medications, the decision to use Qutenza during pregnancy should involve careful assessment of the benefits versus potential risks. If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor before treatment.

Breastfeeding should be discontinued before Qutenza treatment. It is not known whether capsaicin or its metabolites are excreted in human breast milk. Given the limited systemic absorption following topical application, the risk to a breastfed infant is likely low, but as a precautionary measure, breastfeeding should be stopped prior to treatment.

Children and Adolescents

Qutenza is not recommended for use in patients under 18 years of age. The safety and efficacy of capsaicin 8% patches have not been established in the pediatric population, and there are insufficient data to make dosing recommendations for children and adolescents.

Driving and Using Machines

No studies have been conducted on the effect of Qutenza on the ability to drive or operate machinery. Because only very small amounts of capsaicin enter the bloodstream and remain there for a very short time, it is unlikely that Qutenza would have any direct effect on concentration, coordination, or the ability to drive or use machines. However, patients should consider their overall pain condition and any concurrent medications that may impair these abilities.

How Does Qutenza Interact with Other Drugs?

Because Qutenza is applied topically and capsaicin acts locally at the site of application, the systemic absorption of the active ingredient is minimal and transient. Consequently, Qutenza is not expected to interact with other systemically administered medications. No formal drug–drug interaction studies have demonstrated clinically relevant pharmacokinetic or pharmacodynamic interactions with Qutenza.

This low interaction profile is one of the notable advantages of Qutenza compared to systemic neuropathic pain medications. Patients with peripheral neuropathic pain are often older adults who take multiple medications for comorbid conditions such as diabetes, hypertension, and cardiovascular disease. The addition of Qutenza to their treatment regimen is unlikely to alter the efficacy or safety of their existing medications.

However, there are some practical considerations regarding the concurrent use of certain medications:

It is always important to inform your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins, before receiving Qutenza treatment. While direct pharmacological interactions are unlikely, your doctor needs a complete picture of your medication regimen to provide safe and effective care.

What Is the Correct Dosage of Qutenza?

Qutenza has a unique dosing approach compared to conventional medications. Rather than daily pills or scheduled doses, it is administered as a single in-clinic application that provides sustained pain relief for up to 12 weeks. The dosage is determined by the size of the painful area rather than by body weight or patient characteristics.

Adults

The application process follows a strict clinical protocol. Before placement, the healthcare provider identifies and marks the most painful areas on the skin. The treatment area is washed with soap and water and dried thoroughly. Any hair in the area is clipped (not shaved) to ensure good patch adhesion. A topical anesthetic such as lidocaine cream may be applied to reduce discomfort during the procedure; this must be completely removed and the skin cleaned again before the Qutenza patch is placed.

The healthcare provider wears gloves, and may use a face mask and protective goggles when handling the patches. The patch can be cut into smaller pieces to fit the treatment area precisely. After the specified application time (30 or 60 minutes), the patch is removed by the healthcare provider – patients must not attempt to remove it themselves.

Following patch removal, the treated skin is cleaned with the cleansing gel provided in the Qutenza kit. The gel is left on the skin for one minute and then wiped away to remove any residual capsaicin. The area is then gently washed with soap and water.

Children

Qutenza is not recommended for patients under 18 years of age. There is insufficient clinical evidence to establish safe and effective dosing for children and adolescents. Alternative neuropathic pain treatments should be considered for pediatric patients under the guidance of a specialist.

Elderly Patients

No dose adjustment is required for elderly patients. Clinical trials have included substantial numbers of patients aged 65 years and older, and the safety and efficacy profile was comparable to younger adults. However, elderly patients are more likely to have cardiovascular comorbidities, so careful blood pressure monitoring during the procedure is particularly important in this population.

Missed Dose

The concept of a missed dose does not apply to Qutenza in the traditional sense, as it is not a medication taken on a regular schedule. If a planned treatment appointment is missed, it should be rescheduled at the earliest convenient time. If pain relief from a previous treatment wears off before the 90-day retreatment interval, consult your doctor to discuss timing of the next application.

Overdose

Overdose with Qutenza is unlikely given the controlled clinical setting in which it is applied. However, if the patch is left on for longer than the recommended duration, more severe local reactions may occur at the application site, including increased pain, redness, blistering, and skin irritation. In the event of accidental prolonged exposure, the patch should be removed immediately and the skin treated with the cleansing gel. Symptomatic treatment for local reactions (cooling, analgesics) should be provided as needed. There is no specific antidote for capsaicin overdose.

What Are the Side Effects of Qutenza?

Like all medicines, Qutenza can cause side effects, although not every patient will experience them. The majority of side effects are localized to the application site and are a direct consequence of capsaicin’s pharmacological action on pain nerve endings. Most application-site reactions are mild to moderate in severity and resolve within days to weeks after treatment.

The application-site burning and redness are expected pharmacological effects of capsaicin and typically peak within the first few hours of treatment. Most patients report that these symptoms diminish substantially within 1–5 days. The temporary blood pressure elevation during treatment is related to the pain of the application rather than a direct cardiovascular effect of capsaicin, and it typically resolves once the patch is removed and pain subsides.

Long-term safety data from repeated application studies have shown that side effects do not increase in frequency or severity with repeated treatments. The nerve fiber reduction caused by capsaicin is reversible, and normal nerve fiber density gradually returns between treatments. Importantly, Qutenza has not been associated with permanent nerve damage or loss of protective sensation in properly conducted clinical trials.

If you experience any side effects that concern you, or if side effects persist beyond what your healthcare provider has indicated as normal, consult your doctor promptly. Reporting side effects helps regulatory authorities continuously monitor the benefit-risk balance of medications.

How Should You Store Qutenza?

As Qutenza is administered exclusively in healthcare settings, patients will not typically need to store this medication at home. However, understanding proper storage is important for healthcare professionals and pharmacists handling the product, as well as for patients who wish to be fully informed about their treatment.

Qutenza cutaneous patches must be stored flat in their original sealed pouches and outer carton to protect them from light and environmental exposure. The storage temperature must not exceed 25°C (77°F). The accompanying cleansing gel should also be stored below 25°C. Both components should be kept out of the sight and reach of children at all times.

Once the sealed pouch has been opened, the Qutenza patch must be applied within 2 hours. The patch must not be used after the expiration date printed on the carton. The expiration date refers to the last day of the stated month.

Used and unused Qutenza patches retain residual capsaicin and can cause burning if touched with bare skin. Healthcare professionals should handle used patches with nitrile gloves and place them in a polyethylene disposal bag before discarding according to local waste disposal regulations. Treatment materials that have come into contact with capsaicin should be similarly handled.

What Does Qutenza Contain?

Understanding the full composition of Qutenza is important for patients with known allergies or sensitivities to specific pharmaceutical excipients. The Qutenza system consists of two components: the capsaicin cutaneous patch and a cleansing gel for post-application skin care.

Cutaneous Patch Composition

The active substance is capsaicin. Each 280 cm² patch contains a total of 179 mg capsaicin, which equates to 640 micrograms of capsaicin per square centimeter (8% by weight). The patch has a three-layer structure:

• Adhesive matrix layer (contains the active ingredient): silicone adhesive, diethylene glycol monoethyl ether, silicone oil, ethylcellulose N50 (E462)
• Backing layer (outer surface): polyethylene terephthalate (PET) film with siliconized inner surface, printing ink containing Pigment White 6; the outer surface is stamped with “capsaicin 8%”
• Release liner (removable protective film): polyester film coated with fluoropolymer; this clear, diagonally-cut liner is removed before application

Cleansing Gel Composition

The cleansing gel is supplied in a 50 g tube and does not contain any active pharmaceutical ingredient. Its purpose is to remove residual capsaicin from the skin after patch removal. The gel contains:

• Macrogol 300
• Carbomer
• Purified water
• Sodium hydroxide (E524)
• Disodium edetate
• Butylated hydroxyanisole (E320)

Packaging

Each Qutenza carton contains either 1 or 2 individually sealed pouches (each containing one patch) and 1 tube of cleansing gel (50 g). Not all pack sizes may be marketed in all countries. Each patch measures 14 cm × 20 cm (280 cm²) and can be cut to size to fit the specific treatment area.